Clinical Trials Sponsored by NHS Camden

Total 8332 results

Amgen

Completed

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Gastric Cancer | Esophageal Cancer | Esophagogastric Junction Adenocarcinoma
Amgen

Completed

Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenic Purpura
Amgen

Withdrawn

Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With Asthma

Asthma
Amgen

Terminated

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis

Psoriasis

United States
Amgen

Completed

A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density

Osteoporosis | Osteopenia | Low Bone Mineral Density
Amgen

Completed

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

Thyroid Cancer
Amgen

Completed

Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density

Low Bone Mineral Density
Amgen

Completed

A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

Osteoporosis
Amgen

Completed

Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease

Chronic Kidney Disease | Kidney Disease
Amgen

Completed

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

Cancer | Anemia
Amgen

Completed

SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism

End Stage Renal Disease | Secondary Hyperparathyroidism
Amgen

Completed

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

Tumors
Amgen

Completed

Enbrel® in Psoriatic Arthritis

Psoriasis
Amgen

Completed

Chemotherapy Related Anemia

Anemia | Non-Myeloid Malignancies
Amgen

Completed

Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors

Normal PBPC Donors
Amgen

Completed

A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis

End Stage Renal Disease | Secondary Hyperparathyroidism
Amgen

Completed

A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

Anemia | Non-Myeloid Malignancies
Amgen

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis

Psoriasis

New Zealand, Australia
Amgen

Terminated

First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia

Schizophrenia

United States
Amgen

Completed

Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Amgen

Completed

Study of Transitioning From Alendronate to Denosumab

Postmenopausal Osteoporosis
Amgen

Completed

A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma

Cancer | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Thrombocytopenia | Oncology | Chemotherapy-Induced Thrombocytopenia
Amgen

Completed

Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates

Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast Cancer | Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Amgen

Completed

A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate

Rheumatoid Arthritis
Amgen

Completed

Study to Evaluate Effectiveness of Aranesp®

Kidney Disease
Amgen

Completed

Single-dose, Pharmacokinetics of AMG 853 in Healthy Adult Subjects

Healthy Volunteers
Amgen

Completed

Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia

Anemia | Congestive Heart Failure
Amgen

Completed

ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

Neoplasm Metastasis | Lung Cancer | Non-small Cell Lung Cancer
Amgen

Completed

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Breast Cancer | Non-Hodgkin's Lymphoma | Ovarian Cancer | Lung Cancer | Neutropenia
Amgen

Completed

Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy

Sarcoma | Neutropenia
Amgen

Completed

A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer

Breast Cancer
Amgen

Completed

Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis

End Stage Renal Disease
Amgen

Completed

Heart Failure and Anemia

Heart Failure | Anemia
Amgen

Completed

Treatment for Subjects With Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma
Amgen

Completed

Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis

Chronic Kidney Disease | Kidney Disease
Amgen

Completed

Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies

Lymphoma | Breast Neoplasms | Lung Neoplasms | Multiple Myeloma | Chronic Lymphocytic Leukemia
Amgen

Completed

Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis
Amgen

Completed

Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer

Ovarian Cancer
Amgen

Completed

START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism

Chronic Kidney Disease | Secondary Hyperparathyroidism | Kidney Disease
Amgen

Completed

A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia

Neoplasms | Anemia
Amgen

Completed

Anemia in Patients With a Non-Myeloid Malignancy

Neoplasms | Anemia
Amgen

Terminated

Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)

Chronic Kidney Disease
Amgen

Completed

Treatment for Patients With Osteoarthritis (OA)

Osteoarthritis
Amgen

Completed

Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis

Kidney Disease
Amgen

Completed

Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease

Anemia | Kidney Disease
Amgen

Completed

Post Transplant Study

Hyperparathyroidism | Secondary Hyperparathyroidism | Kidney Tansplant
Amgen

Completed

Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy

Anemia | Non-Small Cell Lung Cancer
Amgen

Completed

Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis
Amgen

Completed

ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

Neoplasm Metastasis | Non-Small Cell Lung Cancer | Lung Cancer
Glasgow Caledonian University
NHS Greater Glasgow and Clyde; NHS Lanarkshire

Completed

TAIC: Student-led Exercise for Older Adults at Risk of Falling (TAIC)

Exercise | Falls

United Kingdom

3

Subscribe